selenium has been researched along with carboplatin in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Avila, J; Cortés, P; Gill, M; Pizarro, I; Rivera, L; Román, DA; Torres, C | 1 |
| Buckley, B; Caffrey, PB; Frenkel, GD; Gibbon, DG; Gounder, M; Hellmann, M; Kane, MP; Kumaran, MN; Nieves-Neira, W; Rodriguez-Rodriguez, L; Shih, W; Song, M; Vaidya, A | 1 |
| Kim, HS; Lee, M; Lee, N; Lee, S; Paik, H; Park, SJ; Yim, GW | 1 |
2 trial(s) available for selenium and carboplatin
| Article | Year |
|---|---|
Phase I trial of selenium plus chemotherapy in gynecologic cancers.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Carboplatin; Cell Line, Tumor; Chemotherapy-Induced Febrile Neutropenia; DNA-Binding Proteins; Down-Regulation; Female; Gene Expression; Glutathione Peroxidase; Humans; Infections; Lung Diseases; Maximum Tolerated Dose; Middle Aged; Nervous System Diseases; Ovarian Neoplasms; Paclitaxel; Response Evaluation Criteria in Solid Tumors; RNA-Binding Proteins; Selenious Acid; Selenium; Selenoprotein P | 2018 |
Efficacy and safety of intravenous administration of high-dose selenium for preventing chemotherapy-induced peripheral neuropathy in platinum-sensitive recurrent ovarian, fallopian or primary peritoneal cancer: study protocol for a phase III, double-blind
Topics: Administration, Intravenous; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Clinical Trials, Phase III as Topic; Female; Humans; Neoplasm Recurrence, Local; Ovarian Neoplasms; Paclitaxel; Peripheral Nervous System Diseases; Pharmaceutical Preparations; Platinum; Quality of Life; Randomized Controlled Trials as Topic; Selenium | 2021 |
1 other study(ies) available for selenium and carboplatin
| Article | Year |
|---|---|
Urinary excretion of platinum, arsenic and selenium of cancer patients from the Antofagasta region in Chile treated with platinum-based drugs.
Topics: Antineoplastic Agents; Arsenic; Biomarkers; Carboplatin; Chile; Cisplatin; Cluster Analysis; Creatinine; Female; Humans; Linear Models; Lung Neoplasms; Male; Multivariate Analysis; Platinum; Selenium | 2012 |